<span item_type="fundamental" item_id="336fb277ede2977f7a6971e18ae3e84d" counter_id="ST/US/HTFB" env="prod"></span><span item_type="announcement" item_id="510673551434190849" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.53.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Investment Income</strong>: Total investment income for the three months ended March 31, 2025 was $24,516, compared to $26,129 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1487428/000143774925013547/hrzn20250331_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Investment Income</strong>: Net investment income before excise tax for the three months ended March 31, 2025 was $11,097, compared to $12,984 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1487428/000143774925013547/hrzn20250331_10q.htm"></span></li><li><strong>Net Realized and Unrealized Loss</strong>: Net realized and unrealized loss for the three months ended March 31, 2025 was -$32,155, compared to -$3,952 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1487428/000143774925013547/hrzn20250331_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: Net cash used in operating activities for the three months ended March 31, 2025 was -$13,185, compared to $4,041 provided by operating activities for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1487428/000143774925013547/hrzn20250331_10q.htm"></span></li><li><strong>Net Cash Used in Financing Activities</strong>: Net cash used in financing activities for the three months ended March 31, 2025 was -$10,219, compared to -$8,430 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1487428/000143774925013547/hrzn20250331_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Distributable Loss</strong>: Distributable loss as of March 31, 2025 was -$216,873, compared to -$182,061 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1487428/000143774925013547/hrzn20250331_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Horizon Technology Finance Corporation aims to continue focusing on secured debt and venture lending investments to venture capital-backed companies in technology, life science, healthcare information and services, cleantech, and sustainability industries.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1487428/000143774925013547/hrzn20250331_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is involved in various sectors including biotechnology, medical devices, and sustainability, with investments in companies like Castle Creek Biosciences, Inc., Emalex Biosciences, Inc., and Pivot Bio, Inc.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1487428/000143774925013547/hrzn20250331_10q.htm"></span></li></ul>

Horizon Tech Finance Pref Shares HTFB 4.875 03/30/26 | 10-Q: FY2025 Q1 EPS: USD -0.53